Table 2.
Clinical characteristics of patients
| Characteristic | Number | % | |
|---|---|---|---|
| Age, years | |||
| Median | 54.1 | ||
| Range | 39–74 | ||
| Sex | |||
| Male | 118 | 74.2 | |
| Female | 41 | 25.8 | |
| PS | |||
| 0 | 77 | 48.4 | |
| 1 | 65 | 40.9 | |
| 2 | 17 | 10.7 | |
| Histology | |||
| Adenocarcinoma | 81 | 50.9 | |
| Squamous cell carcinoma | 67 | 42.5 | |
| Large‐cell carcinoma | 7 | 4.4 | |
| Others | 4 | 2.5 | |
| Pathologic stage | |||
| III | 96 | 60.4 | |
| IV | 63 | 39.6 | |
| Chemotherapy regimen | |||
| Platinum + Paclitaxel | 56 | 35.2 | |
| Platinum + Taxotere | 42 | 26.4 | |
| Platinum + Gemcitabine | 33 | 20.8 | |
| Platinum + Vinorelbine | 23 | 14.5 | |
| Platinum + others | 5 | 3.1 | |
| Treatment response | |||
| CR | 8 | 5.0 | |
| PR | 34 | 21.4 | |
| SD | 78 | 49.1 | |
| PD | 39 | 24.5 | |
Abbreviation: PS, performance status; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.